Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: Tislelizumab
- drug: BGB-A425
- drug: LBL-007
Eligibility
Inclusion Criteria:
- Participants with histologically or cytologically confirmed R/M HNSCC that is
considered incurable by local therapies
1. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx,
and larynx
2. Participants should not have had prior systemic therapy administered in the R/M
setting; systemic therapy which was completed prior to randomization/enrollment
if given as part of multimodal treatment for locally or locoregionally advanced
disease is allowed
- Participants must have positive PD-L1 expression (Combined Positive Score [CPS] ≥ 1)
- Have at least 1 measurable lesion as defined per RECIST v1.1
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Adequate hematologic and organ function as indicated by specific laboratory values
within 7 days of first dose of study drug
- Willing to use a highly effective method of birth control for the duration of the
study and for ≥ 120 days after the last dose of study drug(s)
Exclusion Criteria:
- Recurrent or metastatic carcinoma of the nasopharynx (any histology), squamous cell
carcinoma of unknown primary, squamous cell carcinoma that originated from the skin
and salivary gland primary tumor or non-squamous histologies (eg, mucosal melanoma)
- Prior therapy with an anti-PD-1, anti-PD-L1, PD-L2, T-cell immunoglobulin and mucin
domain containing-3 (TIM-3), LAG-3, or any other antibody or drug specifically
targeting T-cell costimulation or immune checkpoint pathways
- Any active malignancy ≤ 2 years before randomization/enrollment except for the
specific cancer under investigation in this study, those with a negligible risk of
metastasis or death, and any locally recurring cancer that has been treated curatively
(eg, resected basal or squamous cell skin cancer, superficial bladder cancer,
localized prostate cancer, and carcinoma in situ of the cervix or breast)
- History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung
diseases including pulmonary fibrosis, and acute lung diseases
- A history of severe hypersensitivity reactions to other monoclonal antibodies or has
experienced a severe immune-mediated adverse event (imAE), an imAE that led to
treatment discontinuation, or a cardiac or ocular imAE of any grade with prior
immunotherapy
Note: Other inclusion and exclusion criteria may apply
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elizabeth (Elzbieta) Winters
650-721-6509
I'm interested
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.